Overview

A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC.

Status:
RECRUITING
Trial end date:
2026-04-30
Target enrollment:
Participant gender:
Summary
To evaluate the clinical efficacy and safety of oral all-trans retinoic acid in combination with toripalimab in patients with locally advanced, recurrent, or metastatic triple-negative breast cancer who had failed second-line and subsequent therapy.
Phase:
NA
Details
Lead Sponsor:
First Affiliated Hospital of Zhejiang University
Collaborators:
Shanghai Longfine Biotechnology Co., Ltd.
TopAlliance
Treatments:
toripalimab